Anxiety disorders affect as many as 30% of children and adolescents, and the children of parents with an anxiety disorder have a higher risk of developing an anxiety disorder than the children of parents [...]
Postpartum psychosis (PPP) is a rare but serious psychiatric illness, occurring in 1 to 2 per 1000 women in the weeks. Because postpartum psychosis is so rare, we do not have specific guidelines regarding [...]
Recent studies have shown that pregnancy and childbirth are frequently associated with the onset of Obsessive Compulsive Disorder (OCD). While most women do not have the full set of symptoms to meet diagnostic criteria for [...]
We are pleased to announce the recent launch of an exciting new research initiative that is being conducted by the Massachusetts General Hospital Center for Women’s Mental Health. The Symptom Tracking in Assisted Reproductive Technologies study (START study) will focus on understanding the risk factors for depressive relapse in women undergoing infertility treatments. There has been a growing request in our clinical work to address the needs of women undergoing infertility treatments. It is our hope that such a study will provide important information on the course and risk of depression in women undergoing fertility treatment and thus inform clinical care.
In a recent retrospective cohort study, data collected from linked records from the Women's and Children's Health Network in South Australia were used to investigate neonatal outcomes in children exposed prenatally to selective serotonin reuptake inhibitors (SSRIs). Women were included in this study if they gave birth to a singleton, live-born infant between September 2000 and December 2008 (n = 33,965).
Over the past few years, there have been a large number of studies which have relied on large administrative databases to generate information on the reproductive safety of various medications. One of the strengths of this type of approach is that it provides an opportunity to observe outcomes in a large number of subjects; however, there are certain, very important limitations. A recent study published in the American Journal of Obstetrics and Gynecology helps to understand some of the challenges in interpreting the data generated from these studies.
Seeking women between 18-45 with PMS who have been diagnosed with depression. If you are between 18 and 45 and:
Are you an expectant mother? Do you have questions about bipolar disorder and antidepressants or mood-stabilizers during pregnancy? If you are pregnant and diagnosed with bipolar disorder (or manic depression), you may be eligible for this research study. Participants meet with research coordinators and psychiatrists who specialize in bipolar illness during pregnancy. For more information about this study, please contact Rachel at (617) 726-2912 or firstname.lastname@example.org.